New treatment reduces alzheimer’s symptoms by 60%


Scientists for the first time successfully stimulated the congenital immune system of monkeys in such a way as to help their own resources to deal with neurodegeneration. The first results are very impressive: therapy has reduced two key signs of dementia and now the team is preparing for clinical trials.

Researchers from New York University presented a new promising therapy of Alzheimer’s disease, which encourages the cells of the immune system to attack toxic protein deposits in the brain — accumulation of beta-amyloid and Tau proteins. These toxic plaques gradually lead to disruption of ties between neurons and their death.

«Our results show that the treatment is an effective way to manipulate the immune system to slow down neurodegeneration,» said Akash Patel co-author.

The basis of CPG Oligodeoxinucleotide Therapy (CPG ODN), which relate to regulators of a congenital immune response,

The team conducted experiments on the models of the Beliche monkeys, which in old age are usually always developing neurodegeneration. The drug was injected with 8 females aged 17 to 19 years for two years once a month. Seven animals from the control group received placebo. Alzheimer’s disease in animals could be classified as progressive neurodegeneration at the last stages.

The effectiveness of therapy was assessed by analyzing brain and blood samples, as well as animal behavior.

There were no such improvements from the monkey from the control group.

Until now, the attempts of therapy aimed at a congenital immune system were not effective, since the medications were too stimulated by the immune system and this led to inflammation. This time, scientists managed to avoid this dangerous complication due to the cyclical administration of the drug. In the breaks, the immune system could relax, which prevented excessive reactions, the authors clarified.

«The similarity in aging between this species and our gaze gives the hope that the therapy will work for both of the person,» the co-author of Henriet Scholtsov said. Currently, the team is preparing for clinical trials for people in the early stages of Alzheimer’s disease.

Recently in the USA

We tell about the most interesting news and technologies — from the upcoming total automation to alternative energy, from artificial intelligence to the future medicine.

Hayk +